We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ray,
I have been looking for developers of COVID-19 antigen specific T cells tests with a view to adding to my portfolio. In terms of investing, it seems all the focus has been on antibody testing but it's looking increasingly likely that T cell testing may also have an important role. So far I've only managed to find a NASDAQ listed (although British) based company who are adapting a TB antigen specific test to COVID. It'll be interesting to see how they get on.
I guess it is too early to say how long immunity will last for any of these vaccines or even whether the immunity is strong enough.
I don't recall anybody measuring populations of the covid19 specific TCells so far on people vaccinated.
I know studies have taken place on levels of TCells for recovered patients.
Also, how well they will perform on older people? The age range 18-55 seems to be the norm for the trials so far.
I might be wrong on these points, so I stand to be corrected.
Just as a comparison the SCIB1 participants had a median age of the mid 60s and they all had either stage 3 or 4 melanoma.
I think the longer term plan is for the UK to set up to sell vaccines to the RoW, and not just for Covid-19. Certainly they need something to provide some good economic news. In the nearer term, being self-sufficient in vaccine manufacture will be critical.
Crucially, it was mentioned that the Oxford vaccine was reliant on having at least two injections.
https://www.ouh.nhs.uk/about/trust-board/2018/may/documents/TB2018.51a-appendix-1.pdf
https://www.dailymail.co.uk/news/article-8326429/UKs-antibody-testing-fiasco-exposed-PHE-test-misses-cases.html
IMO...conflicts of interest all over the shop!
@WTP - yes disappointing lack of probing questions on the strategy.
Next session has Jonathan Van-Tam from University of Nottingham...talking about therapeutics
Sorry replied to the wrong thread:
"IMO this is basically just tributes and adulations to (former Oxford alumini) Kate Bingham and Oxfords Professor Sarah Gilbert.
Where's the perntinent, probing questions? A total shower of shi... IMO."
Seems like an Oxford vaccine whitewash, self congratulatory back slapping session IMO???
As I've kept on saying there seems to be some kind of obvious bias on Oxford and Imperial, everything else is just froth?
P.s. the American is the only one who seems remotley impartial and talking - he mentioned not betting all on the big two as it's a risk.
Kate Bingham, Chair, UK Government Vaccine Taskforce; says she needs more than a billion to deliver her plan which involves multiple vaccines.
Key Comment from Kate Bingham - her plan that is currently submitted to the treasury for approval includes funding for a "Portfolio of vaccines"
Bingham says there is a business case for funding for a portfolio of vaccines, in addition to funding trials, and manufacturing to more than 1BN doses.
John Bell says to place lots of bets.....
I will refrain from making any politically biased observations, but I am concerned the same issue will cascade when an effective vaccine is in place.
Clue here in terms of why Scancell isn't receiving funding? Manufacturing supply chain investment has been focused on adenovirus and mRNA based vaccines.
Bingham has said that if Oxford's vaccine is not effective, it will manufacture others, as well as building up capacity to produce millions of doses within a few months.
Ramping up efficacy trials....
Hence my question LL RE who's taking part? Seems anything but impartial??
I think there will be when they issue the index. Usually you can skip through HoC discussions according to which MP is speaking - they don't have that set up for this Committee
I am not surprised that they are centring on Oxford and then pushing flu vaccines.
Is there a full list of the people taking part?
Disappointing that the T Cell line of question didn't spin out to ask about other approaches specifically designed to induce T Cells.
In the recording, just before 15:00, the started discussing T-Cell response without antibody response. They are saying it is a confounding factor in predicting Herd Immunity, but lost the speaker at a very interesting point.
Oxford (Gilbert) says it produces both t-cell and antibody responses
Currently discussing T cells and Karolinska institute - "Lots of work going on in the UK on this..." Oxford claiming they will get TCell and antibody response...
Kate Bingham cagey because of "commercial considerations". Correct me if i'm wrong, but she did not mention DNA vaccines when listing the possible approaches?
Oxford vaccine being discussed.
However, for the rest, the assumption is that we will have COVID through the next flu season (as discussed in March)
https://parliamentlive.tv/Event/Index/13b1c071-1e7d-4e58-b919-bbe61bc88ad1